{"filing":{"accession_number":"0001104659-26-066974","cik":"0001971387","ticker":"LIMNW","company_name":"Liminatus Pharma, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"tm2615785d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm"},"events":[{"id":8683,"run_id":7625,"accession_number":"0001104659-26-066974","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Liminatus Pharma received notice from Nasdaq on May 20, 2026 that it failed to regain compliance with the MVLS Rule and MVPHS Rule by the May 18, 2026 deadline, resulting in delisting from The Nasdaq Global Market effective May 29, 2026 unless an appeal is granted. The company requested an appeal on May 26, 2026, which stays the delisting pending a hearing. This is a clear delisting notice under Item 3.01.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-05-27","submitted_at":null,"items":[{"id":1828,"accession_number":"0001104659-26-066974","item_number":"3.01","item_title":"Notice of Delisting or Failure to","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Liminatus Pharma received notice from Nasdaq on May 20, 2026 that it failed to regain compliance with the MVLS Rule and MVPHS Rule by the May 18, 2026 deadline, resulting in delisting from The Nasdaq Global Market effective May 29, 2026 unless an appeal is granted. The company requested an appeal on May 26, 2026, which stays the delisting pending a hearing. This is a clear delisting notice under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:10:05.090881+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1828,"accession_number":"0001104659-26-066974","item_number":"3.01","item_title":"Notice of Delisting or Failure to","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Liminatus Pharma received notice from Nasdaq on May 20, 2026 that it failed to regain compliance with the MVLS Rule and MVPHS Rule by the May 18, 2026 deadline, resulting in delisting from The Nasdaq Global Market effective May 29, 2026 unless an appeal is granted. The company requested an appeal on May 26, 2026, which stays the delisting pending a hearing. This is a clear delisting notice under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:10:05.090881+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-05-27"}]}